Clinical Trials Browser

Ramucirumab × Head & Neck × 90 days × Clear all

NCT03650764 2026-05-15

Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Phase 1/2 Completed

Squamous Cell Carcinoma of Head and Neck

NCT05980000 2026-03-31

Rambro2

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms